The Phase 3 REFALS trial exploring the impact of oral levosimendan (ODM-109) in patients with amyotrophic lateral sclerosis (ALS) has completed its target enrollment, the therapy’s manufacturer, Orion, announced. A total of 496 participants were recruited across 104 sites in the United States, Canada, Europe, and Australia. They…
Enrollment Completed for Phase 3 REFALS Trial Evaluating Levosimendan in ALS Patients
A study in identical twins or triplets found that changes in DNA marks, collectively known as DNA methylation and typically associated with aging, can like genetics play an important role to determining the development of amyotrophic lateral sclerosis (ALS). The four sets of ALS-affected and unaffected siblings carried age-related differences…
Researchers have created the first entirely human small chip that is able to replicate some of the cell-cell interactions occurring in the peripheral human nervous system, according to a recent study. The Nerve-on-a-Chip platform, developed by AxoSim using organ-on-chip technology, promises to help researchers understand, faster and at…
I am by nature a fixer. After my husband, Todd, was diagnosed with ALS, I found out modern medicine didn’t provide a cure. There’s no option for surgery. No drugs significantly improve outcomes. So, I turned to searching the internet for alternative therapies that might help. “I want to fight…
Men with benign prostatic hyperplasia (BPH) — prostate gland enlargement — are not at greater risk of amyotrophic lateral sclerosis (ALS) and similar disorders, according to a nationwide study in Denmark. “We found no evidence of an increased risk of ALS and other MND [motor neuron diseases] among…
The challenges Vesna Aleksovska faced when she decided a decade ago to help fellow Macedonians with rare diseases were so daunting, they would have scared off all but the most determined. At that time, few doctors in the developing country of 2 million — now called North Macedonia — had…
“For the past two weeks, you have been reading about a bad break. Yet today, I consider myself the luckiest man on the face of the earth.” —Lou Gehrig, July 4, 1939 Lou Gehrig was my father’s favorite baseball player, which for a fair bit of my youth,…
Masitinib in combination with Rilutek (riluzole) slows functional decline of patients with amyotrophic lateral sclerosis (ALS) who have a typical disease progression, according to the final report of AB Science‘s Phase 2/3 clinical trial. At 11 months of treatment with…
Posture impairments in amyotrophic lateral sclerosis (ALS) are linked to deficits in trunk control and in the mechanisms that control the body’s response to surface tilts. Moreover, these abnormalities also correlated to disease severity. Those findings are in the study “Abnormal trunk control determines postural abnormalities in Amyotrophic…
News
Small-Molecule Compounds ID’d That May Lessen Protein Buildup in Cells Under Stress, an ALS Hallmark
Researchers identified small-molecule compounds that help to prevent the build-up of stress-induced clumps of TDP-43 protein, a hallmark of amyotrophic lateral sclerosis (ALS). These findings, although preliminary, may lead to new therapies for ALS. The work “Small-Molecule Modulation of TDP-43 Recruitment to Stress Granules Prevents Persistent TDP-43 Accumulation in…
Recent Posts
- Shionogi completes acquisition of rights to ALS drug Radicava
- New rare gene variants tied to ALS risk in large international genetic analysis
- ALS patients, caregivers prefer team-based care model, new survey finds
- ALS partnership to give 6 patients expanded access to TRE-515
- Frustration mounts when ALS assistive technology isn’t so helpful